Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Gross Margin (2022 - 2025)

Oramed Pharmaceuticals' Gross Margin history spans 3 years, with the latest figure at 0.65% for Q1 2025.

  • For Q1 2025, Gross Margin changed N/A year-over-year to 0.65%; the TTM value through Dec 2025 reached 0.65%, changed N/A, while the annual FY2025 figure was 0.65%, N/A changed from the prior year.
  • Gross Margin reached 0.65% in Q1 2025 per ORMP's latest filing, down from 71.51% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 72.37% in Q1 2023 to a low of 0.65% in Q1 2025.
  • Average Gross Margin over 3 years is 38.61%, with a median of 37.87% recorded in 2022.
  • The largest YoY upside for Gross Margin was 6096bps in 2023 against a maximum downside of 2789bps in 2023.
  • A 3-year view of Gross Margin shows it stood at 32.11% in 2022, then soared by 123bps to 71.51% in 2023, then plummeted by -99bps to 0.65% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Gross Margin are 0.65% (Q1 2025), 71.51% (Q2 2023), and 72.37% (Q1 2023).